The acquisition of Humaskan involves a $10 million cash payment alongside $50 million in Davion ordinary shares, priced at $13.00 per share with a nine-month lock-up period. This follows the recent purchase of Solar Medical and Chemical Limited, which provided Davion with its primary commercial and distribution hub in the United Kingdom.

To fuel further growth, Davion intends to establish Davion Healthcare Finance Ltd. The new entity is expected to initiate a corporate bond program of up to £100 million. These bonds, which carry an indicative 10.5% fixed coupon and a five-year maturity, are intended for professional and institutional investors. The company plans to seek admission for these instruments on the Vienna Stock Exchange MTF platform, with activities potentially commencing in August 2026.

CEO Jack Kaye stated that the dual strategy of acquiring proprietary technology and securing long-term institutional capital provides a flexible foundation for the company’s platform. The board anticipates that this approach will accelerate product development and manufacturing capabilities while allowing for disciplined capital deployment across target healthcare sectors.